UNSPSC 51161720: Roflumilast

This classification denotes a phosphodiesterase inhibitor with the molecular formula C17H14Cl2F2N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0P6C6ZOP5U, chemically known as 3-cyclopropylmethoxy-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide but generally known as roflumilast, which bears US NIH Compound Identifier 449193. European Medicines Agency schedules Roflumilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10358MIG.

UNSPSC 51161720 Roflumilast is a Commodity code representing a specific pharmaceutical product, but the recent state and local contracting activity under this code does not center on roflumilast itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement and pharmacy services contracting across multiple jurisdictions and issuing bodies. State and local governments are using this code classification to solicit pharmaceutical products and related services including naloxone and drug deactivation systems, on-site pharmacy services delivery, direct-to-manufacturer prescription programs, and generic pharmaceuticals and OTC products through cooperative purchasing. Issuing bodies span county health departments (Seminole County, Florida), county government employee health programs (Hall County, Georgia), state health agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Department of Administration). The code shows activity across health care procurement, pharmacy benefit administration, and emergency response product sourcing, though the nominal code name does not align precisely with the actual work being solicited.

Recent opportunities cluster in Florida, Georgia, Texas, and Minnesota. Seminole County, Florida issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. Hall County, Georgia released an RFQ/P for on-site pharmacy services at the Hall County Government Family Health Center Clinic to serve approximately 3,005 eligible individuals in the county's group health insurance plans, with responses due June 4, 2026 and a 80/20 technical-to-cost evaluation weighting. The Texas HHS Commission posted an RFI in April 2026 to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration released an RFP for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, serving participating state and local facilities across multiple jurisdictions. The code shows scattered but active procurement spanning emergency response pharmaceuticals, employer health plan pharmacy services, direct-supply models, and cooperative purchasing arrangements.